CoChat

A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Background/aims Patients with primary sclerosing cholangitis (PSC) have an increased risk of developing cholangiocarcinoma (CC), which is notoriously difficult to diagnose since these patients may have increased levels of bilirubin due to benign strictures. To evaluate the validity of different tumor markers as an aid to diagnosing CC, we have carried out serial serum tumor marker analyses in patients with PSC who have been followed for several years.Methods Seventy-five patients with PSC, without any clinical signs of CC were included in the study. They were investigated every 6th months for 3 years, with extensive liver function tests and four tumor serum markers CEA, CA 19-9, CA 50 and CA 242. The patients were then followed for 5 years to exclude the possibility that CC remained unrecognized.Results Of the 75 patients, two (3%) developed CC during the 3-year period. One of these had normal levels, and one had significantly increased levels of the tumor markers. In the follow-up part of the study two further patients died from CC and one from hepatocellular carcinoma, 3 and 4 years after the 3-year study, respectively. Twenty-one patients had an increase of one of the markers on at least one occasion. Five patients had a transient increase of more than double the upper normal limit of the tumor markers on more than one occasion. There was a good correlation between CA 19-9, CA 50 and CA 242, but not with CEA. Fourteen of the 75 patients had periods of increased bilirubin levels, but none of these showed increased tumor markers.Conclusions The serum tumor markers CEA, CA 19-9, CA 50 and CA 242 are of limited value for the detection of CC in patients with PSC because of low specificity. However, we found no falsely increased values in patients with hyperbilirubinemia.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0168-8278(99)80198-6

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Research works printed but not linked: 1

  1. Pagnuzzi, 1988, CA 19–9 and CA 50 in benign and malignant pancreatic and biliary disease, Cancer, 61, 2100, 10.1002/1097-0142(19880515)61:10<2100::aid-cncr2820611028>3.0.co;2-z · doi:10.1002/1097-0142(19880515)61:10<2100::aid-cncr2820611028>3.0.co;2-z

Cited by

See all 107

Metadata

Authors
Hultcrantz, R., Olsson, R., Danielsson, Å., Järnerot, G., Lööf, L., Ryden, B. O., Wahren, B., & Broomé, U.
Affiliations
  • Karolinska University Hospital (SE)
  • Sahlgrenska University Hospital (SE)
  • University Hospital of Umeå (SE)
  • Örebro University Hospital (SE)
  • Uppsala University Hospital (SE)
  • Karolinska Institutet (SE)
Corresponding author
Hultcrantz, Rolf
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
1999-04
Volume
30
Issue
4
Pages
669-673
ISSN
0168-8278 (ISSN-L)
OpenAlex
W2155936309
Cited by
107
References
31
Citations by year
2026: 2 · 2025: 3 · 2024: 3 · 2023: 2 · 2022: 4 · 2021: 3 · 2019: 2 · 2017: 4 · 2015: 5 · 2014: 3 · 2013: 1 · 2012: 4
FWCI
5.51
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of Hepatology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Vetenskapsrådet
Topics
  • Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
Keywords
cholangiocarcinoma, primary sclerosing cholangitis, serum tumor markers, CA19-9, CA50, CA242, carcinoembryonic antigen, cancer detection, hyperbilirubinemia, benign biliary strictures, hepatocellular carcinoma, cancer screening
MeSH terms
Adult, Bile Duct Neoplasms, Bile Ducts, Intrahepatic, Carcinoembryonic Antigen, Colchicine, Double-Blind Method, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Staging, Predictive Value of Tests, Prospective Studies, Risk Factors, Time Factors, Biomarkers, Tumor, Reproducibility of Results, Cholangitis, Sclerosing, Antigens, Tumor-Associated, Carbohydrate, Cholangiocarcinoma, CA-19-9 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. https://app.cochat.ai/papers/10.1016/s0168-8278(99)80198-6
The paper
Hultcrantz, R., Olsson, R., Danielsson, Å., Järnerot, G., Lööf, L., Ryden, B. O., Wahren, B., & Broomé, U. (1999). A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Journal of Hepatology. https://doi.org/10.1016/s0168-8278(99)80198-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.